Comparison of Efficacy of Pembrolizumab between Epstein-Barr Virus‒Positive and ‒Negative Relapsed or Refractory Non-Hodgkin Lymphomas

PURPOSE: Pembrolizumab, a programmed cell death protein 1 (PD1) inhibitor inhibits the interplay between PD1 of T-cell and programmed cell death ligand 1 (PDL1) on tumor cells. Although pembrolizumab has been tried to various subtypes of non-Hodgkin lymphoma (NHL), real-world data about the efficacy...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Seok-Jin, Hyeon, Jiyeon, Cho, Inju, Ko, Young Hyeh, Kim, Won Seog
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6473267/
https://www.ncbi.nlm.nih.gov/pubmed/30025443
http://dx.doi.org/10.4143/crt.2018.191

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6473267/
https://www.ncbi.nlm.nih.gov/pubmed/30025443
http://dx.doi.org/10.4143/crt.2018.191

Ejemplares similares